Market news, stock analysis and investing ideas

Inhibrx Q3 Loss Widens to $2.46 a Share; INBX Fell 5% Before the Report

Inhibrx's third-quarter loss grew to $2.46 per share as interest costs rose on a larger loan. The stock had already closed down 5.07% on Friday before the 4:02 p.m. ET release.

Inhibrx Q3 Loss Widens to $2.46 a Share; INBX Fell 5% Before the Report

Inhibrx Biosciences, Inc. (NASDAQ: INBX) reported third-quarter results at 4:02 p.m. ET on Friday, Nov. 13, after the regular session closed. The company posted a net loss of $38.7 million, or $2.46 per share, and said it held $199.5 million in cash and cash equivalents on Sept. 30. An 8-K filing followed at 4:08 p.m.

A wider loss, with the pipeline timeline intact

Higher interest expense and launch preparation pushed the loss up from $2.28 a share a year earlier, while the clinical timelines in the release were unchanged. The stock's 5.07% drop came during the regular session, before the release, so the report did not cause it. Monday is the first full session that can react to the numbers, so any read on the impact is provisional.

Shares fell before the report; after-hours was quiet

In pre-market trading (the session before the regular open) the stock traded at $87.81, up 0.07% from Thursday's close of $87.75, on 12,669 shares.

The slide came in the regular session. Shares closed at $83.30, down 5.07% from Thursday's close, after trading between $80.68 and $87.91. Volume was 190,908 shares, against a 10-day average of about 260,488.

After-hours trading (the session after the 4 p.m. close) showed almost no reaction. The last trade, at 4:12 p.m., was at $83.30, and only four shares had changed hands.

The stock has been volatile. From Oct. 15 through Thursday it slipped 3.04% overall, with a high of $100.20 on Oct. 22. It fell 23.38% on Oct. 28 and bottomed at $66.80 on Oct. 30. A 12.36% jump on Nov. 3 and an 8.54% gain on Nov. 9 (to $91.74) followed, and Thursday's close came after a 3.14% decline.

Why the numbers carried little surprise

Inhibrx is a clinical-stage company, so its value rests mainly on trial results and the regulatory timeline rather than quarterly revenue. Its market value is $1.21 billion, and its float (shares available for public trading) is about 10.02 million. Revenue of $2.0 million came from a Pfizer license, a small amount next to a $38.7 million loss.

Estimates for the quarter's loss varied, so there is no clean comparison with expectations.

What changed in the quarter

  • Revenue: $2.0 million, from a non-exclusive patent license granted to Pfizer for a $2.0 million upfront payment received in September. Inhibrx recognized no revenue in the third quarter of 2025.
  • Research and development: $26.0 million, down from $28.5 million a year earlier. The company cited lower clinical trial costs after enrollment finished in its chondrosarcoma trial and reduced headcount, partly offset by higher contract manufacturing costs tied to the Biologics License Application (BLA) for ozekibart.
  • General and administrative: $7.8 million, up from $5.3 million, on pre-commercialization work for a possible chondrosarcoma launch.
  • Other expense: $7.0 million, up from $1.4 million, mainly interest on a $275.0 million outstanding loan balance. A year earlier the balance was $100.0 million.
  • Net loss: $38.7 million, or $2.46 per share, against $35.3 million, or $2.28 per share, a year earlier.

The company said commercial readiness activities for ozekibart in chondrosarcoma are advancing in line with the regulatory review timeline.

Upcoming data and trial milestones

  • Nov. 19-20: Inhibrx plans to present updated Phase 1/2 results for ozekibart with irinotecan and temozolomide in refractory Ewing sarcoma at the Connective Tissue Oncology Society meeting in Seoul.
  • Ongoing: Phase 2 enrollment of about 50 more HPV-positive oropharyngeal cancer patients in the HexAgon study of ordastobart with pembrolizumab. The company expects the initial readout around mid-2027, then plans to reach agreement with the FDA on a possible accelerated pathway before it starts the Phase 3 portion.
  • Mid-2027: Initial results from the Phase 1/2 study of ordastobart in perioperative non-small cell lung cancer.

Bottom line

The quarter showed a larger loss from interest on a bigger loan and launch preparation, with $199.5 million in cash against $275.0 million of loan balance outstanding. The Friday drop predates the release, and after-hours trading was too thin to show a reaction. The Ewing sarcoma data on Nov. 19-20 is the next dated event.


This article was processed by WSN Finance AI Analysis and prepared by WSN Editors based on financial analysis.

This article is for informational purposes only and is not investment advice.

Read the original report